Effectiveness of neoton in patients with chronic heart failure depending on the left ventricular ejection fraction. Sub-analysis of the BYHEART study

Aim. To study the effectiveness of exogenous phosphocreatine (EPCr) therapy in patients with heart failure (HF) with reduced and mildly reduce dejection fraction (EF).Material and methods. The all-Russian prospective observational study BYHEART included 842 patients who underwent aEPCr therapy course. Before and after the course of EPCr therapy, the following studies were carried out: a questionnaire on the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the clinical assessment scale (CAS), transthoracic echocardiography with an assessment of the left ventricular EF, a 6-minute walk test, N-terminal pro-brain natriuretic peptide (NT-proBNP). All patients before the EPCr course received long-term optimal therapy for HF.Results. Data analysis was carried out for patients in groups with heart failure with reduced ejection fraction (HFrEF) and with mildly reduced ejection fraction (HFmrEF) within the group depending on the course of EPCr treatment: subgroup A — patients who received EPCr therapy less than 20 g/course and subgroup B — patients who received EPCr therapy ≥20 g/course. The results obtained demonstrate an increase in the quality of life and exercise tolerance, an improvement according to the CAS, a decrease in NT-proBNP levels, and an improvement in left ventricular systolic function in patients with both HFrEF and HFmrEF during the course of intravenous EPCr therapy.Conclusion. The use of EPCr is a promising tool in addition to optimal therapy in patients with HFrEF and HFmrEF.